|
Dana Hilt has had more than 15 years experience in the pharmaceutical industry. After receiving his medical degree from Tufts University School of Medicine in Boston he trained in Internal Medicine at Harvard and Neurology at Johns Hopkins. He was then on the staff of the NIH for five years performing both basic molecular neurobiology research and clinical studies at the NIH clinical center. Dana then was in the Neurology and Molecular Biology Departments at the University of Maryland School of Medicine before joining Amgen to establish a clinical neuroscience group that focused on the potential therapeutic applications of neurotrophic factors in degenerative neurologic diseases. He subsequently held senior development and management positions as Chief Medical Officer at Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. During this time Dana was involved in the development of a variety of potential therapeutics including drugs for Parkinson’s Disease, ALS, Alzheimer’s Disease, oncologic diseases including malignant glioma, chronic pain, metabolic disorders, and inflammatory conditions. At Envivo Pharmaceuticals Dana is responsible for the development of a drug candidate after it is nominated into development from basic research. Dana has co-authored more than 75 publications and book chapters in basic and clinical neuroscience and has participated, chaired, or organized a number of national and international symposia | 